A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma

Completed · Phase 1

Conditions studied: Relapsed Or Refractory Multiple Myeloma

In brief

To determine the maximum tolerated dose and dose limiting toxicity of thymoglobulin in multiple myeloma patients. To determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with Thymoglobulin. To determine the time to response, duration of response, and time to progression and overall survival of patients treated with Thymoglobulin. To determine the safety and tolerability of Thymoglobulin in these patients. To assess the changes in lymphocyte apoptosis and apoptotic signaling in treated patients.

Key facts

Study ID

NCT00545519

Run by

Washington University School of Medicine

People needed

6

Starts

2006-10-01

Expected to finish

2008-03-01

Last updated by the study team

2013-04-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Multiple myeloma diagnosed by standard criteria.
• Measurable levels of monoclonal protein in serum (> 0.5 g/dL) or urine (> 0.2 g/24 hr).
• At least 2 prior therapies for multiple myeloma with documented evidence of progression on the most recent treatment.
• Age 18 years or older.
• ECOG performance status <= 2.
• Acceptable organ and marrow function as defined below:
• Hemoglobin > 8 gm/dL
• Absolute neutrophil count > 1,000/mm3
• Platelets > 50,000/mm3
• Total bilirubin < 2.5 X institutional upper limit of normal
• AST, ALT < 2.5 X institutional upper limit of normal
• Creatinine < 1.5 X institutional upper limit of normal
• Normal cardiac function as determined by standard institutional methods
• Women of child bearing potential must agree to use adequate contraception prior to study entry and for the duration of study.
• Ability to understand and the willingness to sign a written informed consent document.
• Must have demonstrated resistance to steroids equivalent to >160mg/month of dexamethasone, 1g/month of prednisone, or 800mg/month of solumedrol, to insure the effects seen are from thymoglobulin and not the concomitant steroids.

You may not qualify if…

• Receiving any other investigational agents.
• Receiving concurrent steroids with a dose equivalent of dexamethasone of > 200 mg/month, 1.25g/month of prednisone, or 1g/month of solumedrol.
• Pregnant or nursing.
• Active systemic infection considered opportunistic, life threatening or clinically significant at the time of treatment.
• Severe concurrent disease, including severe insulin-dependent diabetes, uncontrolled hypertension, transient ischemic attacks, uncontrolled symptomatic coronary artery disease, or symptomatic CNS involvement or psychiatric illness/social situations that would limit compliance with study requirements.
• History of other malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast unless the subject has been off treatment and free from disease for > 3 years.
• Weight of <100 kg to avoid exceeding maximum allowed steroid dose.

Where it is running

• Washington Unvierstiy in St. Louis — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.